Mounjaro®
Starting from £179.99/mo
Start journey Learn moreThe short answer is no — the licensed schedule does not support a dose increase after only two weeks. The Mounjaro titration plan is designed around four-week intervals at each dose level, a structure the SmPC sets out explicitly and one grounded in how the medicine behaves in the body. Changing dose sooner is not clinically appropriate, and a prescriber would not sanction it. If you are currently two weeks into your starting pen and wondering whether to accelerate things, the evidence is clear: patience at this stage is part of the treatment, not a delay to it.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The Mounjaro Summary of Product Characteristics (SmPC), available on the electronic Medicines Compendium, specifies a minimum of four weeks at each dose before any increase. That interval was not chosen arbitrarily. Tirzepatide is a dual GIP and GLP-1 receptor agonist, which means it slows gastric emptying and alters gut-hormone signalling, two effects that take time to stabilise. The body adjusts across the first weeks of each dose, and that adjustment process is precisely what makes a two-week increase unsafe. There is also a common misconception worth naming gently: some people believe the early weeks produce little effect and that bumping the dose faster will speed results. The trial data do not support this. In SURMOUNT-1, participants following the structured titration schedule achieved an average body-weight reduction of around 20–21% at 15mg over 72 weeks, that outcome was built on the full programme, dose by dose. You can read more about why and when a dose increase makes clinical sense once the minimum interval has passed.
The NHS medicines page for tirzepatide confirms the same titration framework, noting that dose changes are a decision for your prescribing clinician based on tolerability and response, not a patient-initiated adjustment.
The first fortnight on any new Mounjaro dose tends to be the busiest for side effects. Nausea, loose stools, indigestion and fatigue are all more common when the dose has just changed, and they typically ease as the weeks pass. Increasing too soon stacks a second adjustment on top of an unfinished first one, which is why the four-week minimum exists as a safeguard, not a formality. The 5mg dose page covers what to expect when moving from 2.5mg, including the side-effect pattern most people encounter and how it usually resolves. On the question of how many injections a single pen provides, the answer depends on your dose strength and is worth confirming with your prescriber before you think you've run low.
If side effects at week two are significant enough that you are wondering about a change, the right move is to contact your prescriber or clinical support team. Reducing the frequency of injections or pausing briefly may sometimes be considered; increasing the dose would not be.
At nume, sorry, at nume, a GPhC-registered Independent Prescriber personally reviews your case before any dose change is approved. That review looks at how you have tolerated the current dose across the full four weeks, your weight record, and any symptoms you have reported. It is not a tick-box process. A prescriber might recommend staying at your current dose for a further four weeks if tolerability has been difficult, even if the minimum interval has technically elapsed. Conversely, if your four weeks are up and you have settled well, they will assess whether moving up is appropriate. The timing of dose increases is a clinical judgement that your prescriber makes with you, not a date you mark on a calendar yourself.
For anyone weighing up the broader picture of what each dose level involves, our guide to increasing Mounjaro dosage covers the full titration ladder and what the evidence shows at each step. And if you are thinking about what the overall treatment journey looks like, the Mounjaro overview sets out the licence, the clinical evidence and how private access works in the UK.
It rarely is, once you understand the mechanism. The four-week interval is not a commercial decision or a conservative guess, it reflects how tirzepatide is studied and licensed. Most people find that by week three or four they are adjusting well and the early side effects have quietened. If that is not your experience, reach out to the aftercare team; there may be practical steps (meal timing, hydration, injection technique) that make the current dose more comfortable without touching the dose itself. The FAQs page also covers the questions most commonly raised in the first weeks of treatment.
If you have not yet started treatment and are trying to understand how the titration schedule works before committing, a free consultation with a nume prescriber is the place to ask those questions directly. They can talk through the full schedule with you and confirm whether Mounjaro is clinically suitable in your case.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.